(Reuters) - Medical device maker Becton Dickinson and Co (N:BDX) beat quarterly profit estimates on Thursday, aided by higher demand for its COVID-19 diagnostic test kits as the United States ramped up testing for the new coronavirus.
The country, which has recorded at least 158,561 COVID-19 deaths and about 4.8 million cases so far, is running only 800,000 diagnostic coronavirus tests daily, while 6-10 million tests per day are needed, by various estimates.
Revenue in Becton's diagnostics systems unit rose nearly 19% to $184 million, the company said.
Becton Dickinson, which sells a variety of COVID-19 tests, said it was working to ramp up testing capacity for many of them in the event of a second wave of infections in the fall.
The company also benefited from orders received from the United States, UK and Canada for millions of its syringes and needles for COVID-19 vaccination programs.
Excluding items, the company earned $2.20 per share, beating analysts' estimates of $2.04 per share, according to IBES data from Refinitiv.
Sales fell to $3.86 billion from $4.35 billion, compared with the average analyst estimate of $3.94 billion.